Jin Hao, Pang Qing, Liu Huichun, Li Zongkuang, Wang Yong, Lu Yimin, Zhou Lei, Pan Hongtao, Huang Wei
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Medicine (Baltimore). 2017 Jan;96(3):e5895. doi: 10.1097/MD.0000000000005895.
We aimed to assess the therapeutic effect of reimplantation of biliary metal stents by percutaneous transhepatic cholangial drainage (PTCD) in patients with recurrent malignant obstructive jaundice (MOJ). Furthermore, we explored the prognostic value of inflammation-based markers in these patients.We reviewed 33 cases of recurrent MOJ after implantation of biliary metal stents by PTCD, all of which underwent reimplantation of stents under digital subtraction angiography guidance. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin were compared between before and after reimplantation (1 week, 1 month, and 3 months postoperatively). Preoperative clinical data were collected to calculate the inflammation-based markers, including systemic immune-inflammation index (SII, neutrophil × platelets/ lymphocyte), platelets-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). The primary outcome was overall survival (OS), which was estimated by the Kaplan-Meier method and Cox regression analysis.The levels of ALT, AST, total bilirubin, and direct bilirubin significantly reduced after the reimplantation operation. During a median follow-up time of 10 months, 18 (54.5%) patients died. Gender, albumin, SII, PLR, NLR, and MLR were found to be associated with OS by the log-rank test and univariate analysis. Multivariate Cox analysis identified elevated levels of SII and PLR as significant factors for predicting poor OS.Reimplantation is clinically feasible in patients with recurrent MOJ after implantation of biliary metal stents. SII and PLR are independent, useful inflammation-based prognostic models for predicting outcomes in these patients.
我们旨在评估经皮经肝胆道引流术(PTCD)对复发性恶性梗阻性黄疸(MOJ)患者进行胆道金属支架再植入的治疗效果。此外,我们还探讨了基于炎症的标志物在这些患者中的预后价值。我们回顾了33例经PTCD植入胆道金属支架后复发性MOJ的病例,所有病例均在数字减影血管造影引导下进行支架再植入。比较再植入前后(术后1周、1个月和3个月)丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)和胆红素水平。收集术前临床数据以计算基于炎症的标志物,包括全身免疫炎症指数(SII,中性粒细胞×血小板/淋巴细胞)、血小板与淋巴细胞比值(PLR)、中性粒细胞与淋巴细胞比值(NLR)和单核细胞与淋巴细胞比值(MLR)。主要结局为总生存期(OS),采用Kaplan-Meier法和Cox回归分析进行评估。再植入术后ALT、AST、总胆红素和直接胆红素水平显著降低。在中位随访时间10个月期间,18例(54.5%)患者死亡。通过对数秩检验和单因素分析发现,性别、白蛋白、SII、PLR、NLR和MLR与OS相关。多因素Cox分析确定SII和PLR升高是预测OS不良的重要因素。对于胆道金属支架植入术后复发性MOJ患者,再植入在临床上是可行的。SII和PLR是预测这些患者预后的独立、有用的基于炎症的预后模型。